CD43 in the malignant flow cytometry laboratory in 2020

References

• Rosenstein Y, Santana A, Pedraza-Alva G. CD43, a molecule with multiple functions. Immunol Res. 1999;20(3):89–99.
   PubMedGoogle Scholar
• Perkey E, Maurice De Sousa D, Carrington L, et al. GCNT1-mediated O -glycosylation of the sialomucin CD43 is a sensitive indicator of notch signaling in activated T cells. J Immunol. 2020;204(6):1674–1688.
   PubMed Web of Science ®Google Scholar
• Bravo-Adame ME, Vera-Estrella R, Barkla BJ, et al. An alternative mode of CD43 signal transduction activates pro-survival pathways of T lymphocytes. Immunology. 2017;150(1):87–99.
   PubMed Web of Science ®Google Scholar
• Velázquez FE, Anastasiou M, Carrillo-Salinas FJ, et al. Sialomucin CD43 regulates T helper type 17 cell intercellular adhesion molecule 1 dependent adhesion, apical migration and transendothelial migration. Immunology. 2019;157(1):52–69.
   PubMed Web of Science ®Google Scholar
• Pedraza-Alva G, Rosenstein Y. CD43 – one molecule, many tales to recount. Signal Transduct. 2007;7(5–6):372–385. .
   Google Scholar
• Falay M, Öztürk BA, Güneş K, et al. The role of CD200 and CD43 expression in differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Turkish J Hematol. 2018;35(2):94–98.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Juncà J, Sarrate E, et al. Expression of CD43 in chronic lymphoproliferative leukemias. Cytometry B Clin Cytom. 2018;94(1):136–142.
   PubMed Web of Science ®Google Scholar
• Starostka D, Kriegova E, Kudelka M, et al. Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms. Cytometry B Clin Cytom. 2018;94(4):576–587.
   PubMed Web of Science ®Google Scholar
• Arlindo EM, Marcondes NA, Fernandes FB, et al. Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms. Rev Bras Hematol Hemoter. 2017;39(3):252–258.
   PubMedGoogle Scholar
• Falay M, Özet G. Immunophenotyping of chronic lymphocytic leukemia. Clin Lab. 2017;63(10):1621–1626.
   PubMed Web of Science ®Google Scholar
• Falay M, Serdar MA, Dalgali H, et al. Which markers should the used for diagnostic chronic lymphocytic leukemia immunophenotyping scoring system by flow cytometry? Clin Lab. 2019;65(11):2049–2055.
   Web of Science ®Google Scholar
• Hoffmann J, Rother M, Kaiser U, et al. Determination of CD43 and CD200 surface expression improves accuracy of B-cell lymphoma immunophenotyping. Cytometry B Clin Cytom. 2020;98(6):476–482. In press.
   Web of Science ®Google Scholar
• Salem DA, Stetler-Stevenson M. Clinical flow-cytometric testing in chronic lymphocytic leukemia. Methods Mol Biol. 2019;2032:311–321.
   PubMedGoogle Scholar
• Rawstron AC, Kreuzer K-A-A, Soosapilla A, et al., Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European research initiative on CLL (ERIC) & European society for clinical cell analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2018;94(1): 121–128.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Raya M, Vergara S, et al. Refining the limits of borderline lymphoproliferative disorders. Cytom Part B Clin Cytom. 2019;96(5):351–358.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Junca J, Ferra C, et al. FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. Cytom Part B Clin Cytom. 2020;98(5):421–428. In press.
   Web of Science ®Google Scholar
• Salem DA, Scott D, McCoy CS, et al. Differential Expression of CD43, CD81, and CD200 in classic versus variant hairy cell leukemia. Cytometry B Clin Cytom. 2019;96(4):275–282.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Böttcher S, Letestu R, et al. Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013;27(1):142–149.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Fazi C, Agathangelidis A, et al., A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30(4): 929–936.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21(5):956–964.
   PubMed Web of Science ®Google Scholar
• Dowling AK, Liptrot SD, O’Brien D, et al. Optimization and validation of an 8-color single-tube assay for the sensitive detection of minimal residual disease in B-cell chronic lymphocytic leukemia detected via flow cytometry. Lab Med. 2016;47(2):103–111.
   PubMed Web of Science ®Google Scholar
• Durrieu F, Geneviève F, Arnoulet C, et al. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up – a GEIL-GOELAMS study. Cytometry B Clin Cytom. 2011;80(6):346–353.
   PubMedGoogle Scholar
• Cardoso CC, Auat M, Santos-Pirath IM, et al. The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry. Cytometry B Clin Cytom. 2018;94(3):451–458.
   PubMed Web of Science ®Google Scholar
• Szumera-Ciećkiewicz A, Rymkiewicz G, Sokół K, et al. Significance of CD10 protein expression in the diagnostics of follicular lymphoma: A comparison of conventional immunohistochemistry with flow cytometry supported by the establishment of BCL2 and BCL6 rearrangements. Int J Lab Hematol. 2020;42(4):453–463.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Santos-Gomez M, Comes M, et al. Flow cytometry in the differential diagnosis of CD10-positive nodal lymphomas. Lab Med. 2019;51(4):385–393.
   Web of Science ®Google Scholar
• Schniederjan SD, Li S, Saxe DF, et al. A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. Am J Clin Pathol. 2010;133(5):718–726.
   PubMed Web of Science ®Google Scholar
• McGowan P, Nelles N, Wimmer J, et al. Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system. Am J Clin Pathol. 2012;137(4):665–670.
   PubMed Web of Science ®Google Scholar
• Tsagarakis NJ, Papadhimitriou SI, Pavlidis D, et al. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma. Cytom Part B Clin Cytom. 2020;98(5):412–420.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. [Internet]. ( Revised 4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H TJ (Eds), editor. IARC: Lyon 2017.; 2017.
   Google Scholar
• Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8(10):1640–1645.
   PubMed Web of Science ®Google Scholar
• Köhnke T, Wittmann VK, Bücklein VL, et al. Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200. Br J Haematol. 2017;179(3):480–487.
   PubMed Web of Science ®Google Scholar
• Sánchez ML, Almeida J, Vidriales B, et al. Incidence of phenotypic aberrations in series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia. 2002;16(8):1460–1469.
   PubMed Web of Science ®Google Scholar
• Moreau EJ, Matutes E, A’Hern RP, et al., Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol. 1997;108(4): 378–382.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Vitale C, Rossi G, et al. CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. Hematol Oncol. 2018;36(3):543–546.
   Web of Science ®Google Scholar
• Mora A, Bosch R, Cuellar C, et al. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2019;96(2):143–148.
   PubMed Web of Science ®Google Scholar
• Rawstron A, de Tute RM, Shingles J, et al. Improving the differential diagnosis of CD5+ B-lymphoproliferative disorders. EHA Meet. 2016;P586.
   Google Scholar
• Jung G, Eisenmann JC, Thiébault S, et al. Cell surface CD43 determination improves diagnostic precision in late B-cell diseases. Br J Haematol. 2003;120(3):496–499.
   PubMed Web of Science ®Google Scholar
• Zhu J, Raimbault A, Sourdeau E, et al. Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry. Br J Haematol. 2020;190(4):e255–e8.
   PubMed Web of Science ®Google Scholar
• McCarthy BA, Yancopoulos S, Tipping M, et al. A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. Immunol Res. 2015;63(1–3):90–100.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Martínez-Trillos A, et al. Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica. 2017;102(9):e360–e3.
   PubMed Web of Science ®Google Scholar
• van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–1975.
   PubMed Web of Science ®Google Scholar
• Quijano S, López A, Rasillo A, et al. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2008;74(3):139–149.
   PubMedGoogle Scholar
• Autore F, Strati P, Laurenti L, et al. Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: A comprehensive review. Haematologica. 2018;103(6):931–938.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Maluquer C, Junca J. Phenotypic characterization of trisomy 12 monoclonal B-cell lymphocytosis. Cytometry B Clin Cytom. 2018;94(2):374–378.
   PubMed Web of Science ®Google Scholar
• Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996;92(2):382–388.
   PubMed Web of Science ®Google Scholar
• Matutes E, Martínez-Trillos A, Campo E. Hairy cell leukaemia-variant: disease features and treatment. Best Pract Res Clin Haematol. 2015;28(4):253–263.
   PubMed Web of Science ®Google Scholar
• Böttcher S. Minimal residual disease quantification in chronic lymphocytic leukemia: clinical significance and flow cytometric methods. Methods Mol Biol. 2019;1881:211–238.
   PubMedGoogle Scholar
• Santacruz R, Villamor N, Aymerich M, et al. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica. 2014;99(5):873–880.
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol. 2012;30(26):3209–3216.
   PubMed Web of Science ®Google Scholar
• Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980–988.
   PubMed Web of Science ®Google Scholar
• Molica S, Giannarelli D, Montserrat E. Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(7):423–430.
   PubMed Web of Science ®Google Scholar
• Dimier N, Delmar P, Ward C, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131(9):955–962.
   PubMed Web of Science ®Google Scholar
• Thompson M, Brander D, Nabhan C, et al. Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents a review. JAMA Oncol. 2018;4(3):394–400.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016;127(3):279–286.
   PubMed Web of Science ®Google Scholar
• Buyse M, Sargent DJ, Grothey A, et al. Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7(6):309–317.
   PubMed Web of Science ®Google Scholar
• Ghia P, Rawstron A. Minimal residual disease analysis in chronic lymphocytic leukemia: A way for achieving more personalized treatments. Leukemia. 2018;32(6):1307–1316.
   PubMed Web of Science ®Google Scholar
• Little RF, McShane LM. Measure for measure: minimal residual disease in CLL. Blood. 2016;128(24):2747–2748.
   PubMed Web of Science ®Google Scholar
• Thompson PA. MRD negativity as a surrogate for PFS in CLL? Blood. 2018;131(9):943–944.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• Fürstenau M, De Silva N, Eichhorst B, et al. Minimal residual disease assessment in CLL. HemaSphere. 2019;3(5):1.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722–2729.
   PubMed Web of Science ®Google Scholar
• Awan FT. Cure for CLL? Blood. 2016;127(3):274.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-Term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309.
   PubMed Web of Science ®Google Scholar
• Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016;128(24):2770–2773.
   PubMed Web of Science ®Google Scholar
• Hulspas R, O’Gorman MRG, Wood BL, et al. Considerations for the control of background fluorescence in clinical flow cytometry. Cytometry B Clin Cytom. 2009;76(6):355–364.
   PubMedGoogle Scholar
• Azoulay D, Cohen HI, Dementiev E, et al. Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10 + diffuse large B‐cell lymphoma and follicular lymphoma. Cytom Part B Clin Cytom. 2020;98(5):449–453.
   PubMed Web of Science ®Google Scholar
• Wu JM, Borowitz MJ, Weir EG. The usefulness of CD71 expression by flow cytometry for differentiating indolent from aggressive CD10+ B-cell lymphomas. Am J Clin Pathol. 2006;126(1):39–46.
   PubMed Web of Science ®Google Scholar
• Jacob PM, Nair RA, Jayasudha AV, et al. Downregulation of CD10 in leukaemic phase of follicular lymphoma: A silent deception. J Hematop. 2013;6(2):65–70.
   Web of Science ®Google Scholar
• Younes SF, Beck AH, Ohgami RS, et al. The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am J Clin Pathol. 2011;135(5):697–708.
   PubMed Web of Science ®Google Scholar
• Choi SM, Betz BL, Perry AM. Follicular lymphoma diagnostic caveats and updates. Arch Pathol Lab Med. 2018;142(11):1330–1340.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Triguero A, Feliu E, et al. Difference in CD5 and CD10 expression according to anatomic site. Int J Lab Hematol. 2018;40(1):e4–e7.
   PubMed Web of Science ®Google Scholar
• Mitrovic Z, Ilic I, Nola M, et al. CD43 Expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma. 2009;9(2):133–137.
   PubMedGoogle Scholar
• Mitrovic Z, Iqbal J, Fu K, et al. CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphoma. Br J Haematol. 2013;162(1):87–92.
   PubMed Web of Science ®Google Scholar
• Ma XB, Zheng Y, Yuan HP, et al. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. Hum Pathol. 2015;46(4):593–599.
   PubMed Web of Science ®Google Scholar
• Merli M, Arcaini L, Boveri E, et al. Assessment of bone marrow involvement in non-Hodgkin’s lymphomas: comparison between histology and flow cytometry. Eur J Haematol. 2010;85(5):405–415.
   PubMed Web of Science ®Google Scholar
• Statuto T, Valvano L, Calice G, et al. Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. Leuk Res. 2020;88:106267.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Cañamero E, Miljkovic MD. Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry. Blood Rev. 2020 (in press). doi: 10.1016/j.blre.2020.100778
   Google Scholar
• Rothstein TL, Griffin DO, Holodick NE, et al. Human B-1 cells take the stage. Ann N Y Acad Sci. 2013;1285(1):97–114.
   PubMedGoogle Scholar
• Covens K, Verbinnen B, Geukens N, et al. Characterization of proposed human B-1 cells reveals pre-plasmablast phenotype. Blood. 2013;121(6):5176–5183.
   PubMedGoogle Scholar
• Li W, Batliwalla F, Rothstein TL. Human B-1 cells are not preplasmablasts: analysis of microarray data and other issues. Blood. 2013;122(22):3691–3693.
   PubMed Web of Science ®Google Scholar
• Covens K, Verbinnen B, Jacquemin M, et al. Response: extended analysis of microarray data does not contradict preplasmablast phenotype of human CD20+CD27+CD43+ cells. Blood. 2013;122(22):3693–3694.
   PubMed Web of Science ®Google Scholar
• Tangye SG. To B1 or not to B1: that really is still the question! Blood. 2013;121(26):5109–5110.
   PubMed Web of Science ®Google Scholar
• Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70-. J Exp Med. 2011;208(1):67–80.
   PubMed Web of Science ®Google Scholar
• Defendenti C, Atzeni F, Malandrin S, et al. Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases. Int Immunopharmacol. 2018;54:329–335.
   PubMed Web of Science ®Google Scholar
• Wu Q, Mills EA, Wang Q, et al. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis. JCI Insight. 2020;5:3.
   Web of Science ®Google Scholar
• Demoersman J, Pochard P, Framery C, et al. B cell subset distribution is altered in patients with severe periodontitis. PLoS One. 2018;13(2):e0192986.
   PubMed Web of Science ®Google Scholar
• Martin PA, Christina GW, Teodosio C, et al. The nature of circulating CD27 +CD43 + B cells. J Exp Med. 2011;208(13):2565–2566.
   PubMed Web of Science ®Google Scholar